Weight loss pills for diabetics with type 2 diabetes are an increasingly important part of managing both body weight and blood glucose control. Excess weight — particularly abdominal fat — drives insulin resistance, making glycaemic management more challenging. In the UK, several NICE-approved medicines are available, including GLP-1 receptor agonists such as semaglutide (Wegovy®) and liraglutide (Saxenda®), as well as orlistat. Each works differently, carries distinct eligibility criteria, and interacts with existing diabetes treatments in specific ways. This article explains how these medicines work, who qualifies for NHS treatment, and what to discuss with your GP or diabetes team.

How Weight Loss Medicines Work in Type 2 Diabetes

Weight management is a cornerstone of type 2 diabetes care. Excess body weight — particularly around the abdomen — contributes to insulin resistance, making it harder for the body to regulate blood glucose effectively. Medicines used to support weight loss in people with type 2 diabetes work through several different mechanisms, and many have the added benefit of directly improving glycaemic control.

The most clinically significant class of medicines in this area are GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). In the UK, two products containing semaglutide are available: Wegovy® (semaglutide 2.4 mg), which is licensed specifically for chronic weight management, and Ozempic® (semaglutide up to 1 mg), which is licensed for the treatment of type 2 diabetes. These are distinct licences and the products should not be used interchangeably. Liraglutide is similarly available as Saxenda® (licensed for weight management) and Victoza® (licensed for type 2 diabetes). GLP-1 receptor agonists mimic the action of the naturally occurring GLP-1 hormone, which is released after eating. They work by:

• Stimulating insulin secretion in a glucose-dependent manner

• Suppressing glucagon release, reducing hepatic glucose output

• Slowing gastric emptying, which promotes a feeling of fullness

• Acting on appetite centres in the brain, reducing overall calorie intake

Another medicine, orlistat (Xenical®, Alli®), works differently — it inhibits pancreatic lipase in the gut, preventing approximately one-third of dietary fat from being absorbed. Whilst orlistat does not directly lower blood glucose, the resulting calorie deficit and weight loss can meaningfully improve insulin sensitivity over time.

It is important to understand that these medicines are not standalone solutions. They are intended to complement a reduced-calorie diet and increased physical activity. The degree of weight loss achieved varies between individuals, and clinical benefit is typically seen when medicines are used consistently alongside lifestyle modification.

UK licensing information is available via the electronic Medicines Compendium (eMC) and the MHRA. Prescribing decisions should be guided by current NICE technology appraisals and the British National Formulary (BNF).

NHS-Approved Options for Weight Management in Type 2 Diabetes

In the UK, several medicines are available for weight management in people with type 2 diabetes, though NHS access depends on individual clinical circumstances and local integrated care board (ICB) commissioning decisions.

Semaglutide (Wegovy®) received MHRA approval for chronic weight management in adults and has been recommended by NICE (technology appraisal TA875, 2023) for use in adults meeting specific eligibility criteria (see below). It is administered as a once-weekly subcutaneous injection, with a dose-escalation schedule over several months. NICE guidance specifies that Wegovy® must be prescribed within a specialist weight management service providing dietary, physical activity, and behavioural support, and that treatment is typically for a maximum of two years. It is important to note that Ozempic® should not be prescribed solely for weight loss — its licence is for type 2 diabetes management, and using it off-label for weight loss alone is not appropriate.

Liraglutide (Saxenda®) is a once-daily injectable GLP-1 receptor agonist licensed specifically for weight management and recommended by NICE under TA664. Its use has become less prominent following the availability of semaglutide, which generally produces greater weight reduction, but it remains an option for eligible patients.

Orlistat is the most widely available oral weight loss medicine on the NHS in the UK. It is available on prescription (Xenical® 120 mg) or over the counter at a lower dose (Alli® 60 mg). Whilst its weight loss effects are more modest compared to GLP-1 receptor agonists, it remains a viable option for patients who cannot tolerate or access injectable therapies. It is worth noting that naltrexone–bupropion (Mysimba®) holds a UK marketing authorisation for weight management, but it is not routinely commissioned by NICE and NHS availability is very limited and variable by ICB.

Tirzepatide (Mounjaro®), a dual GIP/GLP-1 receptor agonist, has received MHRA approval for the treatment of type 2 diabetes. NICE has also issued guidance on its use in obesity (TA1026, 2024), and its role in weight management for people with type 2 diabetes is evolving. Patients should discuss current NHS availability with their GP or diabetes team, as commissioning arrangements continue to develop.

References: NICE TA875 (semaglutide 2.4 mg); NICE TA664 (liraglutide 3 mg); eMC SmPCs for Wegovy®, Ozempic®, Saxenda®, Victoza®, Xenical®, Alli®, and Mounjaro®.

Eligibility Criteria and NICE Guidelines

Access to weight loss medicines on the NHS is governed by NICE guidelines and local ICB policies. Not everyone with type 2 diabetes will automatically qualify, and eligibility is assessed on a case-by-case basis.

For semaglutide (Wegovy®), NICE guidance (TA875) specifies that it should be offered to adults who meet all of the following criteria:

• BMI of 35 kg/m² or above (or 32.5 kg/m² or above in people of South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean family background, where health risks occur at lower BMI thresholds; a similar adjustment applies to other Asian backgrounds — clinicians should refer to current NICE guidance for the full list)

• At least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• Engagement in a specialist weight management service offering dietary, physical activity, and behavioural support, delivered by a multidisciplinary team

Treatment with Wegovy® is typically for a maximum of two years as per TA875. Continued prescribing is conditional on demonstrating a clinically meaningful response — specifically, at least 5% weight loss after 12 weeks at the maintenance dose. If this threshold is not met, treatment should be discontinued.

For liraglutide (Saxenda®), NICE guidance (TA664) applies similar principles. The stopping rule requires at least 5% weight loss after 12 weeks at the 3 mg maintenance dose; if not achieved, treatment should be stopped.

For orlistat, NICE guidance (CG189, Obesity: identification, assessment and management) recommends it should be considered for adults with a BMI of 28 kg/m² or above with associated risk factors (including type 2 diabetes), or a BMI of 30 kg/m² or above without risk factors, provided they have made meaningful lifestyle changes first. The stopping rule for orlistat is at least 5% weight loss after 3 months of treatment; if this is not achieved, the medicine should generally be discontinued.

Local NHS availability can vary, and some patients may experience delays or restrictions depending on their ICB. Your GP or diabetes team can advise on what is currently commissioned in your area.

References: NICE TA875; NICE TA664; NICE CG189.

Potential Side Effects and Safety Considerations

As with all medicines, weight loss treatments used in type 2 diabetes carry a risk of side effects. Understanding these helps patients make informed decisions and recognise when to seek medical advice.

GLP-1 receptor agonists (semaglutide, liraglutide) most commonly cause gastrointestinal side effects, particularly during dose escalation:

• Nausea and vomiting — the most frequently reported effects, usually transient

• Diarrhoea or constipation

• Abdominal discomfort or bloating

• Reduced appetite — generally considered a therapeutic effect but can occasionally lead to inadequate nutrition

More serious but rare adverse effects include:

• Acute pancreatitis — patients should seek urgent medical attention if they experience severe, persistent abdominal pain

• Gallbladder disease (cholelithiasis and cholecystitis) — rapid weight loss can increase the risk of gallstones. Seek prompt medical advice if you develop right upper quadrant pain, nausea, or jaundice

• Diabetic retinopathy — rapid improvement in blood glucose control has been associated with worsening of diabetic retinopathy in some patients, particularly those with pre-existing retinopathy who are also using insulin. Your diabetes team should assess your eyes before and during treatment if this applies to you

• Dehydration and acute kidney injury (AKI) — prolonged vomiting or diarrhoea can lead to dehydration. If you are unable to keep fluids down, seek urgent medical advice via NHS 111 or, in an emergency, 999

• Thyroid concerns — animal studies have raised a theoretical signal regarding thyroid C-cell changes; no causal link has been established in humans. UK prescribing information advises caution in patients with a history of thyroid disease; discuss any concerns with your prescriber

GLP-1 receptor agonists should not be used during pregnancy or whilst breastfeeding. If you are planning a pregnancy, current guidance advises stopping semaglutide at least two months before attempting to conceive. Discuss contraception and family planning with your GP or diabetes team before starting treatment.

Orlistat causes side effects primarily related to its mechanism of action — unabsorbed fat passing through the gut can lead to:

• Oily or fatty stools

• Faecal urgency or incontinence

• Flatulence with oily discharge

These effects are often worsened by high-fat meals and can be managed by adhering to a low-fat diet. Orlistat may also reduce the absorption of fat-soluble vitamins (A, D, E, and K), so a multivitamin supplement taken at a different time of day (e.g., at bedtime) is often recommended. Rarely, orlistat has been associated with oxalate nephropathy.

If you experience severe diarrhoea whilst taking orlistat and use oral contraceptives, additional contraceptive precautions (such as barrier methods) should be used, as absorption may be impaired.

Patients should always report new or worsening symptoms to their GP or diabetes team promptly. Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

References: eMC SmPCs for Wegovy®, Ozempic®, Saxenda®, Xenical®, Alli®; MHRA Yellow Card Scheme.

How These Medicines Interact With Diabetes Treatments

People with type 2 diabetes are often prescribed multiple medicines simultaneously, so understanding potential interactions between weight loss treatments and existing diabetes therapies is essential for safe prescribing.

GLP-1 receptor agonists are frequently used alongside other glucose-lowering agents. When combined with insulin or sulphonylureas (such as gliclazide or glimepiride), there is an increased risk of hypoglycaemia (low blood sugar), because GLP-1 receptor agonists enhance insulin secretion. In practice, the dose of insulin or sulphonylurea may need to be reduced when initiating GLP-1 therapy. Patients should be counselled on the signs and symptoms of hypoglycaemia:

• Shakiness, sweating, or palpitations

• Confusion or difficulty concentrating

• Pallor and weakness

GLP-1 receptor agonists should not be used in combination with DPP-4 inhibitors (such as sitagliptin or alogliptin), as both act on the same GLP-1 pathway and the combination offers no additional benefit whilst increasing the risk of side effects. This combination is not recommended by NICE or the BNF.

Conversely, GLP-1 receptor agonists used alongside metformin or SGLT-2 inhibitors (such as dapagliflozin or empagliflozin) carry a lower risk of hypoglycaemia, as these agents do not stimulate insulin secretion independently.

Because GLP-1 receptor agonists slow gastric emptying, they can affect the absorption of other oral medicines. Medicines with a narrow therapeutic index — such as warfarin — may require closer monitoring when GLP-1 therapy is started or the dose is changed.

Orlistat can affect the absorption of certain oral medicines by altering gut transit time and fat absorption. Key interactions include:

• Ciclosporin — co-administration with orlistat is not recommended, as orlistat may reduce ciclosporin absorption unpredictably. If co-administration cannot be avoided, ciclosporin levels should be monitored closely and doses separated by at least three hours

• Levothyroxine — orlistat may reduce absorption; monitor thyroid function and separate doses by several hours

• Anticoagulants (e.g., warfarin) — orlistat may affect vitamin K absorption and alter anticoagulant effect; INR should be monitored more closely when starting orlistat

• Anticonvulsants — orlistat may reduce absorption of some antiepileptic medicines; monitor for changes in seizure control

Because weight loss itself improves insulin sensitivity, blood glucose levels may fall as patients lose weight — even without changes to their diabetes medication. Regular monitoring and timely medication review by the diabetes team are therefore important to avoid over-treatment and hypoglycaemia as weight decreases.

References: BNF (GLP-1 receptor agonists, DPP-4 inhibitors, orlistat); eMC SmPCs for relevant medicines; NICE NG28 (Type 2 diabetes in adults: management).

Talking to Your GP or Diabetes Team About Your Options

If you have type 2 diabetes and are considering medicines to support weight loss, the most important first step is an open, informed conversation with your GP or diabetes care team. Weight management in diabetes is highly individual, and the right approach depends on your overall health, current medications, BMI, and personal preferences.

Before your appointment, it may be helpful to:

• Keep a record of your current weight and BMI — your GP surgery can help calculate this

• Note any previous attempts at weight loss, including dietary changes, physical activity, or prior use of weight loss medicines

• List all current medications, including over-the-counter products and supplements

• Raise any concerns about side effects, injection-based treatments, or cost

Your GP or diabetes team will assess whether you meet the eligibility criteria for NHS-funded treatment and discuss realistic expectations. It is important to understand that weight loss medicines are most effective when used as part of a comprehensive programme that includes dietary support and physical activity — they are not a substitute for lifestyle change.

If you are referred to a specialist weight management service (sometimes called a Tier 3 service), this will typically involve input from dietitians, psychologists, and specialist nurses who can provide tailored support. For some people with type 2 diabetes and a high BMI, metabolic (bariatric) surgery may also be considered — your GP or specialist can advise whether this is appropriate for you based on NICE criteria (CG189).

Contact your GP or diabetes team promptly if you experience:

• Severe or persistent nausea, vomiting, or abdominal pain — if severe, seek urgent help via NHS 111 or 999

• Symptoms of hypoglycaemia

• Unexplained changes in your blood glucose readings

• Signs of gallbladder problems (right-sided abdominal pain, nausea, or yellowing of the skin or eyes)

• Any new or concerning symptoms after starting a new medicine

Suspected side effects from any medicine should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Remember, there is no single 'best' option for everyone. The goal is to find a safe, sustainable approach that supports both your weight and your long-term diabetes management.

References: NICE CG189 (Obesity: identification, assessment and management); NICE NG28 (Type 2 diabetes in adults: management); NHS weight management services; MHRA Yellow Card Scheme.

Frequently Asked Questions